Sign up for updates

Vote NO · state

38

AUTHORIZES BONDS FOR IMMUNOLOGY MEDICAL RESEARCH. INITIATIVE STATUTE.

What it does

Authorizes $8.4 billion in general obligation bonds for immunology and immunotherapy research, half to a single University of California-affiliated nonprofit medical research institute, half to research grants. Fiscal Impact: Increased state cost of $500 million to $600 million annually for about 20 years to repay the research bond, with some or all of the cost offset if the funded research generates revenue.

Why Thrive LA opposes 38

Proposition 38 authorizes $8.4 billion in state general obligation bonds for immunology and immunotherapy research. Half the money, $4.2 billion, goes to a single University of California-affiliated nonprofit research institute. The other half funds research grants to public and nonprofit institutions. The state's nonpartisan Legislative Analyst estimates repayment will cost $500 million to $600 million a year for about 20 years, paid from the same General Fund that covers public safety, roads, and every other core state obligation. Medical research matters. This measure is the wrong way to fund it. Proposition 38 is borrowing, and borrowing is a tax deferred: every dollar of principal and interest comes out of future budgets or future tax bills. It names no offsetting spending cuts. Backers promise that revenue from future discoveries will repay the state, but the Legislative Analyst calls that revenue uncertain, and any payoff could take decades to arrive, if it arrives at all. The structure is the bigger problem. The measure never names the institute that receives the first $4.2 billion, yet its eligibility criteria are written so narrowly that, according to CalMatters reporting, a UCLA spokesperson confirmed only one nonprofit qualifies: the California Institute for Immunology and Immunotherapy, co-founded and chaired by the measure's chief backer, billionaire Gary K. Michelson. That same institute would also help steer which projects win the other $4.2 billion in grants. Voters are being asked to write a blank check to a single organization without being told its name. The measure also layers on market distortions: a mandated price discount for California patients on resulting treatments and in-state purchasing requirements for funded research. Both raise costs and shrink the incentive for private investment, the engine that already drives most American medical innovation. Robert Kaplan, a Stanford School of Medicine scholar and former associate director of the National Institutes of Health, has publicly opposed the measure. Vote No on Proposition 38.

Key points

  • Decades of New Debt: The Legislative Analyst estimates repayment at $500 million to $600 million a year for about 20 years. That money comes out of the General Fund with no identified spending cuts to cover it.
  • $4.2 Billion, One Recipient: Half the bond goes to a single UC-affiliated institute that the measure never names. Reporting indicates only the California Institute for Immunology and Immunotherapy, chaired by the measure's chief backer, can meet the eligibility criteria.
  • Speculative Payback Promises: Supporters claim future discoveries will repay taxpayers. The Legislative Analyst calls that revenue uncertain and says it could take decades to materialize.
  • Price Controls and Protectionism: Mandated patient discounts and in-state purchasing requirements distort markets, raise research costs, and discourage the private investment that funds most medical breakthroughs.
  • Insider-Controlled Grant Process: The favored institute would influence which projects receive the remaining $4.2 billion in grants. Public money should be awarded through open competition, not by the same insiders who drafted the measure.

See your full ballot

Get a personalized voter guide with every endorsed race + measure on your June 2 ballot.

Get your full voter guide